Print

HPTN 084

Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women

Trial Details:

III Scheduled
National Institute of Allergy and Infectious Diseases (NIAID) October 01, 2017
Cabotegravir
Malawi 3200
NCT03164564
https://clinicaltrials.gov/ct2/show/NCT03164564